EYEMATE-SC Trial: IOP Measurement via an Implantable Sensor

EYEMATE-SC Trial: IOP Measurement via an Impl...

Up next

Ophthalmology Transfers to an Academic Trauma Center

Dr. Edmund Tsui is joined by Dr. Shu Feng, author of Ophthalmology's Assessing the Efficacy of Ophthalmic Transfers to an Academic Level 1 Trauma Hospital, to discuss her study of ophthalmic transfers to an academic level 1 trauma center and the accuracy of transferring diagnoses ...  Show more

American Glaucoma Society's 40th Anniversary

We're celebrating the American Glaucoma Society's 40th Anniversary! Dr. Emily Schehlein interviews three glaucoma luminaries, previous AGS Presidents, and guest editors for Ophthalmology Glaucoma's AGS 40th Anniversary special issue: Dr. Steven Gedde, Dr. Carla Siegfried, and Dr. ...  Show more

Recommended Episodes

Trial highlights from EACTS Annual Meeting 2023
A Cut Above: Cardiothoracic insights from EACTS

Join our hosts Can Gollmann-Tepeköylü and Miia L Lehtinen for their late-breaking trials highlights presented at the 37th EACTS Annual Meeting in Vienna, including: 

<ul type="disc"> <li class="MsoNormal">(2:40 - 8:53) Subann ...  Show more

409. Journal Club: The ARREST-AF Trial with Drs. Prashanthan Sanders and Mehak Dhande
Cardionerds: A Cardiology Podcast

Join CardioNerds EP Council Chair Dr. Naima Maqsood and Episode Lead Dr. Jeanne De Lavallaz as they discuss the results of the ARREST-AF Trial with expert faculty Dr. Prashanthan Sanders and Dr. Mehak Dhande. Audio editing by CardioNerds intern Bhavya Shah. The ARREST-AF trial en ...  Show more

Evolut Low-Risk Trial: 5-year Data Outcomes
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Transcatheter aortic valve replacement (TAVR) has emerged as the preferred treatment for aortic stenosis. However, there is a lack of long-term outcome data for low-risk patients. The 5-year results from the Evolut Low-Risk randomized trial address this gap, offering compelling e ...  Show more

Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

The DapaTAVI trial, conducted across 39 centers in Spain, is the first study to evaluate the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, specifically dapagliflozin, in patients with heart failure undergoing transcatheter aortic valve implantation (TAVI). The trial ...  Show more